Erlotinib vs Pembrolizumab

Erlotinib vs Pembrolizumab: Overview

This comparison examines the pharmacological differences between Erlotinib and Pembrolizumab.

Mechanism of Action

Erlotinib: Reversible inhibitor of EGFR (HER1) tyrosine kinase, blocking autophosphorylation.

Pembrolizumab: Anti-PD-1 monoclonal antibody restoring anti-tumor immunity.

Pharmacokinetics

Half-life: Erlotinib — 36 hours; Pembrolizumab — 26 days.

Chemical Properties

Molecular Formula: Erlotinib — C22H23N3O4.

Molecular Weight: Erlotinib — 393.4380 g/mol.

Type: Erlotinib — Small molecule; Pembrolizumab — Antibody.